



IAP6 Rec'd PCT/PTO 03 FEB 2006 PCT

PATENT  
ATTORNEY DOCKET: 66611.000013

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/553,869 Confirmation No.: 1881  
Applicant : Rikke Hoegh LORENTSEN, et al.  
Filed : October 21, 2005  
Title : CLEAVAGE OF FUSION PROTEIN USING GRANZYME B  
PROTEASE  
TC/Art Unit : Unassigned  
Examiner: : Unassigned  
  
Docket No. : 66611.000013  
Customer No. : 21967

**MAIL STOP AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08A (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

In accordance with 37 C.F.R. § 1.98(a)(2)(ii), copies of cited U.S. patents and/or U.S. patent application publications under 35 U.S.C. 371, are not being provided.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references (other than indicated above) is enclosed with this communication. In considering the cited references, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as 'drawing the Examiner's attention either to

selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.


In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: February 3, 2006

By:

  
Stanislaus Aksman  
Registration No. 28,562

Hunton & Williams LLP  
Intellectual Property Department  
1900 K Street, N.W.  
Suite 1200  
Washington, DC 20006  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)  
SA/asc



<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Application Number</b>	<b>10/553,869</b>
		<b>Filing Date</b>	<b>October 21, 2005</b>
		<b>First Named Inventor</b>	<b>Rikke Hoegh LORENTSEN, et al.</b>
		<b>Art Unit</b>	<b>TBA</b>
		<b>Examiner Name</b>	<b>TBA</b>
<b>Sheet</b>	<b>1 of 2</b>	<b>Attorney Docket Number</b>	<b>66611.000013</b>

### U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US- 6,010,883	01-04-2000	Nagai, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

EXAMINER SIGNATURE	DATE CONSIDERED
--------------------	-----------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

### FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code Number-Kind Code (if known)					YES	NO
	2.	WO	03/010204	02-06-2003	Lee, et al.		<input type="checkbox"/>	<input type="checkbox"/>
	3.	WO	94/18227	08-18-1994	Thøgersen, et al.		<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE	DATE CONSIDERED
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

<b>Application Number</b>	<b>10/553,869</b>
<b>Filing Date</b>	<b>October 21, 2005</b>
<b>First Named Inventor</b>	<b>Rikke Hoegh LORENTSEN, et al.</b>
<b>Art Unit</b>	<b>TBA</b>
<b>Examiner Name</b>	<b>TBA</b>
<b>Attorney Docket Number</b>	<b>66611.000013</b>

**Sheet** **2 of 2**

## OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	4.	Studier, et al., "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes", Methods in Enzymology, Vol. 185, pg. 60-89, 1990.	<input type="checkbox"/>	<input type="checkbox"/>
	5.	Nykjaer, et al., "Purified $\alpha_2$ -Macroglobulin Receptor/LDL Receptor-related Protein Binds Urokinase Plasminogen Activator Inhibitor Type-1 Complex", The Journal of Biological Chemistry, Vol. 267, No. 21, pg. 14543-14546, July 25, 1992.	<input type="checkbox"/>	<input type="checkbox"/>
	6.	Holtet, et al., "Tetranectin, a trimeric Plasminogen-binding C-type Lectin", Protein Science, Vol. 6, pg. 1511-1515, 1997.	<input type="checkbox"/>	<input type="checkbox"/>
	7.	Hochuli, et al., "Genetic Approach to Facilitate Purification of Recombinant Proteins with a Novel Metal Chelate Adsorbent", Biotechnology, pg. 1321-1325, November 1988.	<input type="checkbox"/>	<input type="checkbox"/>
	8.	Christensen, et al., "Sequence-Specific Binding of the N-Terminal Three-Finger Fragment of Xenopus Transcription Factor IIIA to the Internal Control Region of a 5S RNA Gene", Federation of European Biochemical Societies, Vol. 281, No. 1-2, pg. 181-184, April 1991.	<input type="checkbox"/>	<input type="checkbox"/>
	9.	Casciola-Rosen, et al., "Cleavage by Granzyme B is Strongly Predictive of Autoantigen Status: Implications for Initiation of Autoimmunity", Journal of Experimental Medicine, Vol. 190, No. 6, pg. 815-825, September 20, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	10.	Trapani, "Granzymes: a Family of Lymphocyte Granule Serine Proteases", Genome Biology, Vol. 2, No. 12, 2001.	<input type="checkbox"/>	<input type="checkbox"/>
	11.	Sun, et al. "Expression and Purification of Recombinant Human Granzyme B From Pichia pastoris", Biochemical and Biophysical Research Communications, Vol. 261, pg. 251-255, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	12.	Harris, et al., "Definition and Redesign of the Extended Substrate Specificity of Granzyme B", The Journal of Biological Chemistry, Vol. 273, No. 42, pg. 27364-27373, October 16, 1998.	<input type="checkbox"/>	<input type="checkbox"/>
	13.	Sun, et al., "Importance of the P4' Residue in Human Granzyme B Inhibitors and Substrates Revealed by Scanning Mutagenesis of the Proteinase Inhibitor 9 Reactive Center Loop", The Journal of Biological Chemistry, Vol. 276, No. 18, pg. 15177-15184, May 4, 2001.	<input type="checkbox"/>	<input type="checkbox"/>
	14.	Rotonda, et al., "The Three-Dimensional Structure of Human Granzyme B Compared to Caspase-3, Key Mediators of Cell Death with Cleavage Specificity for Asparatic Acid in P1", Chemistry & Biology, Vol. 8, pg. 357-368, 2001.	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.